

Supplementary Fig. S1: Correlation between Variables

A. Correlation matrix; p values

Overall response																				
.747	Patient age																			
.015	.233	Female																		
.114	.311	.409	BRAF ^{V600E}																	
.315	.915	.089	.080	ECOG performance status																
.011	.899	.099	.035	.115	High lactate dehydrogenase (LDH)															
.214	.169	.093	.102	.837	.654	>5 metastasis														
.060	.623	.422	0	.054	.005	.972	High M staging													
.374	.008	.454	0	.014	.071	.990	.016	No. of interleukin-2 (IL-2) doses administered to be patient												
.064	.545	.607	.238	.717	.134	.598	.734	.468	Fold expansion during REP											
.098	.041	.464	.628	.543	.784	.339	.724	.127	0	% CD8 ⁺ cells in infusion product										
.024	.068	.238	.975	.779	.116	.309	.762	.548	0	0	No. of CD8 ⁺ cells in infusion product									
.042	.341	.470	.429	.442	.061	.668	.562	.648	0	0	0	Total no. of TIL in infusion product								
.019	.987	.454	.603	.683	.066	.323	.621	.836	.013	.820	.031	.020	TIL culture period							
.718	.709	.311	.678	.729	.864	.182	.726	.370	.569	.147	.207	.230	.036	Pulmonary congestion						
.790	.534	.320	.976	.237	.976	.553	.410	.664	.102	.603	.298	.071	.235	.769	Renal failure					
.898	.971	.810	.806	.164	.654	.674	.136	.088	.750	.332	.598	.704	.182	.038	.553	Hypotension				
.114	.792	.567	.008	.637	.524	.122	.017	.518	.919	.204	.569	.704	.427	.866	.648	.561	Hyperbilirubinemia			
.744	.212	.360	.581	.057	.741	.095	.043	.204	.852	.685	.755	.697	.209	.828	.790	.521	.169	Diarrhea		
.414	.624	1	.152	.297	.821	.334	.367	.157	.456	.915	.624	.327	.379	.459	.364	.661	.465	.503	Prior IL-2	
.937	.266	.374	.004	.607	.728	.366	.025	.003	.023	.112	.012	.006	.349	.372	.138	.554	.354	.096	.006	Prior ipilimumab

B. Correlation matrix; Kendall's τ coefficient

